Biotechnology Biocad Keen to Enter European Market
Russian biotechnology company, Biocad has plans to enter the European market with oncological and autoimmune medicines. The last phase of the clinical trials are currently underway.
Russia – There are seven molecules in the European portfolio of Biocad. These are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis. Biocad will continue negotiations with the Japanese pharmaceutical partner and discuss commercial terms and conditions for the distribution of its products in the Land of the Rising Sun.
Currently, the Russian pharmaceutical company has not only biosimilars and generics in its pipeline, but also original molecules for the treatment of oncological and autoimmune diseases. The company invests in clinical trials of all this products. The last preparations are underway for conducting the European Phase III clinical trials of adalimumab biosimilar and the original anti-IL-17 molecule.